Two Companies Sell the Same Instrument and Disagree by Twenty-Two Points About What Business They Are In

Editorial analysis accompanying the Global IVD Reagents and Consumables Market Report, 2026–2033.

Two companies published their revenue by category in the same year and, reading the two disclosures side by side, appear to be in different industries.

Sysmex, for the year to March 2026, reports reagents of JPY 307,923 million against instruments of JPY 103,232 million, service of JPY 69,275 million and an “other” line of JPY 19,575 million that includes consumables, on total net sales of JPY 500,006 million. Reagents are 61.58% of the business. Reagents, service and consumables together are 79.35%.

bioMérieux, for calendar 2025, reports reagents of EUR 3,393.2 million against equipment of EUR 282.3 million, services of EUR 254.1 million, equipment rentals of EUR 61.9 million and other revenue of EUR 78.3 million, on a total of EUR 4,069.8 million. Reagents are 83.38%. Equipment is 6.94%.

Both sell closed systems. Both are paid per test. Both put the same physical object in the same kind of laboratory. They disagree by 21.8 percentage points about how much of their business is the consumable.

The rental line is the tell

The difference is not commercial philosophy. It is accounting, and bioMérieux says so in its own note: the equipment-rental line includes revenue reclassified from reagents. The company rents instruments rather than selling them, so the reagent share embedded in that rental is booked as rent rather than as reagent.

Which means the ratio does not describe the industry at all. The razor-and-blade ratio is a property of the contract. A vendor that places instruments and sells reagents reports one number; a vendor that rents instruments and bundles reagents into the rent reports another. Neither is wrong, and neither number is a fact about in vitro diagnostics.

Why the ratio decides what a price cut does

This is where it stops being an accounting curiosity. An administered price reduction lands on whichever line the buyer has chosen to price.

A vendor at 83% reagent content takes that reduction on 83% of revenue, with the instrument cost already committed and no second line to defend. A vendor at 62% reagent content takes it on 62%, and still has an instrument business it can price, bundle or place at a margin when the reagent is being competed away.

The same tender, filed against two different income statements, produces two different outcomes — and which one a company gets was decided when it chose how to sell, years before the tender was announced. Sysmex’s own twenty-year series makes the drift visible: ongoing sales rose from 66.4% to 79.5% of revenue, a 13.1-point migration toward the annuity. That migration is good for margins in a stable price regime and bad in an administered one.

The layer the ratio describes

The reagent and consumable layer is worth USD 78.4 billion in 2025, rising to USD 118.6 billion in 2033 — a 5.31% CAGR, 1.51x, and USD 40.2 billion of incremental annual revenue. That is 72.59% of the USD 108.0 billion in vitro diagnostics base, falling to 70.26% by 2033 because instruments, software and service grow marginally faster than the consumable they carry.

The arithmetic is horizontal, not vertical. Add the instrument and service remainder — USD 29.6 billion, or 27.41% — and you are back at 108.0 exactly. The layer is additive with that remainder and is not additive with the discipline reports beneath it, because a discipline report counts the analyser and this layer counts only what goes into it. Summing the two would count the reagent twice.

Volume rises, price per test falls gently — and the gentleness is mix

Reportable in vitro diagnostic tests are modelled at 47,300 million in 2025 rising to 75,400 million by 2033, a 6.00% CAGR. The layer grows 5.31%. Realised reagent revenue per test therefore falls from USD 1.657 to USD 1.573, a 5.1% decline over eight years, or roughly −0.65% a year.

Set that against clinical chemistry’s −1.3% a year and it looks like health. It is not. The average is being held up by mix: molecular diagnostics consumables grow at 8.00% and take share of the basket, moving the average toward products whose price is not yet administered, while the individual lines inside the basket — immunoassay reagents at 4.55%, chemistry reagents at 3.00% — deflate. An improving average sitting on top of deteriorating components is the most dangerous shape a forecast can have, because it looks stable right up to the point where the mix shift stops.

Where the layer cannot see

Attribution here is the weakest in the cluster: nine disclosed or derived pools total USD 38,228 million, 48.76%, against a stated residual of USD 40,172 million, 51.24%. Four of the five largest diagnostics companies in the world do not publish a reagent split at all, so intensities are applied and printed rather than buried.

The residual is not a research gap. It is the structural inverse of what happens in haematology, where 87.72% of value attributes to named vendors against a 12.28% residual, because a six-part differential cannot be assembled from third-party reagents. A reagent, by contrast, is a recipe. The physical fit is proprietary; the chemistry is not. Thousands of firms — Chinese provincial producers, Indian generic houses, Korean and Brazilian suppliers, every manufacturer of a cuvette, a tip and a sample cup — sit in the middle of this market with no disclosure obligation and no reason to file one.

The cheap half of this market is the half nobody reports. That is a pricing fact before it is a data fact, and it is why a procurement authority that announces a 52.6% average reduction is announcing something the market could not previously see.

Companion analyses in this cluster

A second analysis on this market examines what happens when the reagent itself is the thing tendered, and why a vendor can win the award and still lose the revenue.

Related research: Global IVD Reagents and Consumables Market, 2026–2033; Global In Vitro Diagnostics Market — the USD 108.0 billion base; Global Haematology and Coagulation Diagnostics Market, where the reagent cannot be substituted at all; and Global Clinical Chemistry and Urinalysis Market, where it most nearly can.

Also in this set: Anhui Bought Twenty-Five Reagent Categories at Fifty-Two Point Six Per Cent Off — what happens when the reagent itself is the thing tendered, and why a vendor can win the award and still lose the revenue.

About the method

70% secondary, 30% primary. All figures derive from audited results and statutory filings read from the issuing body — Sysmex’s product-type revenue series and Report 2025, bioMérieux’s FY2025 IFRS 15 revenue note, Danaher’s FY2025 release and 10-K, Bio-Rad’s FY2025 release and 10-K, and Snibe’s 2025 Annual Report. No market-research competitor material is cited, quoted or used to set any level.

The primary layer is 52 depth interviews across 14 markets, 31 open-ended tender-cycle interviews, a 191-respondent laboratory survey and structured observation at four conferences. It establishes mechanism and sequence, carries no figure, and the counts are stated so they can be reconciled against programme records.

Sources

• Sysmex — Net Sales by Destination, Business and Product Type (year to March 2026)
• Sysmex — Sysmex Report 2025 (ongoing sales 66.4% → 79.5%)
• bioMérieux — FY2025 consolidated financial statements (IFRS 15 revenue by category)
• Danaher — Form 10-K, FY2025 (recurring versus non-recurring revenue)
• Bio-Rad Laboratories — Form 10-K, FY2025
• Snibe — 2025 Annual Report (domestic and overseas reagent versus instrument revenue)

Company and entity links

Sysmex Q7663566 · bioMérieux Q2904021 · Danaher Q1159256 · Bio-Rad Q2904022